The synthesis and SAR of a series of indazole TRPV1 antagonists leading to the discovery of 21 (ABT-116) is described. Biological studies demonstrated potent in vitro and in vivo activity for 21, as well as suitable physicochemical and pharmacokinetic properties for advancement to clinical development for pain management. (C) 2010 Elsevier Ltd. All rights reserved.
作者:Brian S. Brown、Ryan Keddy、Richard J. Perner、Stanley DiDomenico、John R. Koenig、Tammie K. Jinkerson、Steven M. Hannick、Heath A. McDonald、Bruce R. Bianchi、Prisca Honore、Pamela S. Puttfarcken、Robert B. Moreland、Kennan C. Marsh、Connie R. Faltynek、Chih-Hung Lee
DOI:10.1016/j.bmcl.2010.04.047
日期:2010.6
The synthesis and SAR of a series of indazole TRPV1 antagonists leading to the discovery of 21 (ABT-116) is described. Biological studies demonstrated potent in vitro and in vivo activity for 21, as well as suitable physicochemical and pharmacokinetic properties for advancement to clinical development for pain management. (C) 2010 Elsevier Ltd. All rights reserved.